Simbrunner, Benedikt
Semmler, Georg
Stadlmann, Alexander
Scheiner, Bernhard
Schwabl, Philipp
Paternostro, Rafael
Bucsics, Theresa
Bauer, David
Eigenbauer, Ernst
Pinter, Matthias
Stättermayer, Albert-Friedrich
Quehenberger, Peter
Marculescu, Rodrig
Trauner, Michael
Mandorfer, Mattias
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Clinical trials referenced in this document:
Documents that mention this clinical trial
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
https://doi.org/10.1007/s12072-020-10112-3
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
https://doi.org/10.1007/s12072-023-10496-y
FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
https://doi.org/10.1007/s12072-023-10636-4
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
https://doi.org/10.1007/s12072-023-10577-y
Funding for this research was provided by:
Gilead Sciences
Medical University of Vienna
Article History
Received: 29 August 2020
Accepted: 10 November 2020
First Online: 8 December 2020
Compliance with ethical standards
:
: BeSi received travel support from AbbVie and Gilead. BeSc received travel support from Abbvie and Gilead. PS received speaking honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim, consulting fees from PharmaIN, and travel support from Falk and Phenex Pharmaceuticals. DB received travel support from AbbVie and Gilead. TB received speaker honoraria from BMS, travel support from Abbvie, BMS, and Gilead; travel grant, financial award/grant from Medis. MP is an investigator for Bayer, BMS, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, and MSD; he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. MT received speaker fees from BMS, Falk Foundation, Gilead, Intercept and MSD; advisory board fees from Albireo, BiomX, Boehringer Ingelheim, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex and Regulus. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. MM has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, W.L. Gore & Associates and Janssen. TR received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. GS, AFS, AS, EE, and RP declare no conflict of interest.
: This study was conducted in accordance with the 1964 Helsinki declaration and its later amendments and approved by the local ethics committee of the Medical University of Vienna (EK1262/2017). All patients gave written informed consent to liver vein catheterizations and provided written consent to be enrolled in the VICIS study (NCT03267615).